CALIFORNIA CAPITAL EQUITY, LLC ACQUIRES 44 MILLION PROMETIC SHARES THROUGH THE EXERCISE OF ALL OUTSTANDING WARRANTS
' LAVAL, QUEBEC, CANADA – February 6, 2017 – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“ProMetic” or the “Corporation”) announced today that California Capital Equity, LLC, has exercised 44,791,488 share purchase warrants at a price of $0.47 per share for total proceeds of $21,051,999.36 to the Corporation.
“Our increased equity position in ProMetic represents a long term and strategic investment for us”, said Dr. Patrick Soon-Shiong, Chief Executive Officer of California Capital Equity, LLC. “ProMetic has robust proprietary therapeutic platforms, promising growth potential and several plasma derived therapeutics expected to reach commercialization stages, starting in 2017 with plasminogen. We, through other investment vehicles, also have an on-going partnership with ProMetic in relation to IVIG and anticipate further collaborations going forward”, added Dr. Soon-Shiong.
Commenting on the exercise of warrants by California Capital Equity, LLC., Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc., said: “We are delighted to see our long-standing relationship with Dr. Soon-Shiong, which dates back to 2008, continue to evolve as we prepare for our first commercial launch in 2017”.'
Jim |
